This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

MSCRG study

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

The Multiple sclerosis collaborative research group study was a double-blind, randomised, placebo-controlled trial of the efficacy of interferon beta-1a in mild relapsing-remitting multiple sclerosis.

Patients had mild multiple sclerosis (EDSS scores 1.0-3.5).

The treatment arm received 30 mcg of interferon beta-1a intramuscularly once per week for 1-2 years.


  • 1) Jacobs, LD, Cookfair, DL, Rudick, RA, at al. (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis: the Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol, 39, 285-94

Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page